VistaGen, a biotechnology company applying human pluripotent stem cell technology to drug rescue and cell therapy, is able to take advantage of a science advisory board with a wealth of experience in dealing with the pharmaceutical industry. It’s a critical asset as the company introduces its revolutionary approach for early drug candidate safety testing, potentially saving major drug companies millions or even billions of dollars over traditional approaches. With an intimate knowledge of the commercial criteria driving Big Pharma, the board is able to apply both scientific expertise and commercial insight into the challenges and opportunities involved in bringing new drugs to the marketplace.
• Gordon Keller, Ph.D., was recently named a “Top 25 Transformational Canadian” for his stem cell research. He’s Director of UHN’s McEwen Centre, and Professor at the Department of Medical Biophysics, University of Toronto, Ontario. He is considered a world leader in the field of hematopoietic development with more than 100 publications relating to blood development and stem cells.
• Peter Backx, Ph.D., D.V.M., has more than 200 publications in electrophysiology, ion channels biochemistry, and heart disease. He has served on several NIH grant study sections, is a reviewer for 69 multiple scientific journals, and has been a past Chair of multiple committees for the Heart & Stroke Foundation of Canada.
• George Clay, Ph.D., is the retired COO of Kyowa Pharmaceuticals, and has 13 years of experience in the worldwide registration of drugs and biologics. He also has many years in preclinical research in neuronal and gastroenterology, as well as drug development and regulatory affairs.
• Arthur Fetter, Ph.D., D.V.M., is the retired Sr. VP of Worldwide Drug Safety for Rhone-Poulenc Rorer, and has over 20 years of veterinary pathology/toxicology and senior management experience in preclinical safety assessment of pharmaceuticals and medical devices.
• Jack Gauldie, Ph.D., is Director at the Centre for Gene Therapeutics, McMaster University, and is recognized internationally for his work in defining the molecular regulation of the acute phase inflammatory response. He is considered a world expert in cytokine biology and the molecular regulation of inflammation and immunity.
• John Lowe, Ph.D., is a retired Sr. Research Fellow of Medicinal Chemistry and Drug Discovery for Pfizer Global R&D, and has authored 88 publications in chemistry, pharmacology, and drug design. He is the inventor or co-inventor on over 60 patents.
• James Sanders, Ph.D., D.V.M., is the retired Sr. Director and Preclinical Development Leader for Johnson & Johnson, and has over 30 years of experience in toxicology, safety assessment, drug development and regulatory affairs in senior global positions at world-leading pharmaceutical companies.
• Ron Wester, Ph.D., is the retired VP of Medicinal Chemistry and Drug Discovery for Pfizer Global R&D, and has nearly 25 years of experience in medicinal chemistry and drug development, with strategic leadership responsibilities for drug discovery technologies across chemistry, biology and computational disciplines.
For additional information on VistaGen Therapeutics, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
